Showing results (151-160 of 162) with videos related to
Sort By:
Pageof 17
Allergy|July 1, 2022
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbationSarah Diver, Koirobi Haldar, Pamela Jane McDowell, et al.American Journal of Respiratory and Critical Care Medicine|June 18, 2011
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersMona Bafadhel, Susan McKenna, Sarah Terry, et al.Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 10, 2020
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)Cary D Austin, Melissa Gonzalez Edick, Ronald E Ferrando, et al.The European Respiratory Journal|September 25, 2021
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthmaJohn Busby, John G Matthews, Rekha Chaudhuri, et al.American Journal of Respiratory and Critical Care Medicine|May 13, 2022
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation PhenotypesP Jane McDowell, John Busby, Catherine E Hanratty, et al.The Journal of Allergy and Clinical Immunology. in Practice|January 9, 2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by SexMatthew C Eastwood, John Busby, David J Jackson, et al.Science Translational Medicine|August 21, 2015
TH2 and TH17 inflammatory pathways are reciprocally regulated in asthmaDavid F Choy, Kevin M Hart, Lee A Borthwick, et al.The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.The Journal of Allergy and Clinical Immunology|June 14, 2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma controlXue Zeng, Jing Qing, Chi-Ming Li, et al.Journal of Medicinal Chemistry|July 12, 2021
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent InhibitorsGiuseppe Campiani, Caterina Cavella, Jeremy D Osko, et al.Pageof 17